HIV Citations List: August 2024

Literature Citations

1. Ripretinib Inhibits HIV-1 Transcription through Modulation of PI3K-AKT-mTOR. Cai, J.F., J.S. Zhou, Z.Y. Meng, Z.Q. Wu, J.C. Zhao, H.X. Peng, X.Y. Liang, J.J. Chen, P.P. Wang, and K. Deng. Acta Pharmacologica Sinica, 2024. 45(8): p. 1632-1643. PMID[38627462]. PMCID[PMC11272926].
[PubMed]. HIV_08_2024.

2. Afucosylated Broadly Neutralizing Antibodies Enhance Clearance of HIV-1 Infected Cells through Cell-Mediated Killing. de Taeye, S.W., A.I. Schriek, J.C. Umotoy, M. Grobben, J.A. Burger, R.W. Sanders, G. Vidarsson, M. Wuhrer, D. Falck, N.A. Kootstra, and M.J. van Gils. Communications Biology, 2024. 7(1): p. 964. PMID[39122901]. PMCID[PMC11316088].
[PubMed]. HIV_08_2024.

3. Human Immunodeficiency Virus Type 1 Gag Polyprotein Modulates Membrane Physical Properties Like a Surfactant: Potential Implications for Virus Assembly. Denieva, Z.G., P.I. Kuzmin, T.R. Galimzyanov, S.A.K. Datta, A. Rein, and O.V. Batishchev. ACS Infect Dis, 2024. 10(8): p. 2870-2885. PMID[38917054]. PMCID[PMC11320576].
[PubMed]. HIV_08_2024.

4. Administration of Anti-HIV-1 Broadly Neutralizing Monoclonal Antibodies with Increased Affinity to Fcγ Receptors During Acute SHIV(AD8-EO) Infection. Dias, J., G. Fabozzi, S. Fourati, X. Chen, C. Liu, D.R. Ambrozak, A. Ransier, F. Laboune, J. Hu, W. Shi, K. March, A.A. Maximova, S.D. Schmidt, J. Samsel, C.A. Talana, K. Ernste, S.H. Ko, M.E. Lucas, P.E. Radecki, K.L. Boswell, Y. Nishimura, J.P. Todd, M.A. Martin, C. Petrovas, E.A. Boritz, N.A. Doria-Rose, D.C. Douek, R.P. Sékaly, J.D. Lifson, M. Asokan, L. Gama, J.R. Mascola, A. Pegu, and R.A. Koup. Nature Communications, 2024. 15(1): p. 7461. PMID[39198422]. PMCID[PMC11358508].
[PubMed]. HIV_08_2024.

5. Potential Anti-HIV and Antitrypanosomal Components Revealed in Sorindeia Nitidula via LC-ESI-QTOF-MS/MS. Ebede, G.R., E.E. Okoro, J. Ngo Mbing, P.H. Diboue Betote, D.E. Pegnyemb, M.I. Choudhary, X. Siwe-Noundou, and J.T. Ndongo. Scientific Reports, 2024. 14(1): p. 18211. PMID[39107384]. PMCID[PMC11303703].
[PubMed]. HIV_08_2024.

6. A Nanoemulsified Formulation of Dolutegravir and Epigallocatechin Gallate Inhibits HIV-1 Replication in Cellular Models. Gaikwad, S.Y., S. Tyagi, C. Seniya, A. More, M. Chandane-Tak, S. Kumar, and A. Mukherjee. Federation of European Biochemical Societies Letters, 2024. 598(15): p. 1919-1936. PMID[38789398].
[PubMed]. HIV_08_2024.

7. Structure and Interactions of HIV-1 gp41 CHR-NHR Reverse Hairpin Constructs Reveal Molecular Determinants of Antiviral Activity. He, L., R. McAndrew, R. Barbu, G. Gifford, C. Halacoglu, C. Drouin-Allaire, L. Weber, L.G. Kristensen, S. Gupta, Y. Chen, C.J. Petzold, M. Allaire, K.H. Li, C.Y. Ralston, and M. Gochin. Journal of Molecular Biology, 2024. 436(16): p. 168650. PMID[38866091]. PMCID[PMC11297672].
[PubMed]. HIV_08_2024.

8. A Fluorescence Polarization Assay for High-Throughput Screening of Inhibitors against HIV-1 Nef-Mediated MHC-I Downregulation. Karimian Shamsabadi, M. and X. Jia. Journal of Biological Chemistry, 2024. 300(8): p. 107529. PMID[38960039]. PMCID[PMC11325787].
[PubMed]. HIV_08_2024.

9. CB-0821, a Novel CC Chemokine Receptor 5 (CCR5) Inhibitor with Improved Binding Efficacy Proposed as Anti-HIV Candidate: Computational and in Vitro Approach. Kumar, A. Biotechnology and Applied Biochemistry, 2024. 71(4): p. 849-859. PMID[38556770].
[PubMed]. HIV_08_2024.

10. KDM5A/B Contribute to HIV-1 Latent Infection and Survival of HIV-1 Infected Cells. Li, T.W., Y. Park, E.G. Watters, X. Wang, D. Zhou, G.N. Fiches, Z. Wu, A.D. Badley, J.B. Sacha, W.Z. Ho, N.G. Santoso, J. Qi, and J. Zhu. Antiviral Research, 2024. 228: p. 105947. PMID[38925368].
[PubMed]. HIV_08_2024.

11. Transcriptional and Methylation Outcomes of Didehydro-cortistatin A Use in HIV-1-Infected CD4(+) T Cells. Mori, L.P., M.J. Corley, A.T. McAuley, A. Pang, T. Venables, L.C. Ndhlovu, M.E. Pipkin, and S.T. Valente. Life Science Alliance, 2024. 7(10). PMID[39089880]. PMCID[PMC11294679].
[PubMed]. HIV_08_2024.

12. Quinolinonyl Derivatives as Dual Inhibitors of the HIV-1 Integrase Catalytic Site and Integrase-Rna Interactions. Patacchini, E., V.N. Madia, A. Albano, G. Ruggieri, A. Messore, D. Ialongo, F. Saccoliti, L. Scipione, S. Cosconati, P.C. Koneru, R. Haney, M. Kvaratskhelia, R. Di Santo, and R. Costi. ACS Medicinal Chemistry Letters, 2024. ISI[001286243200001].
[WOS]. HIV_08_2024.

13. Engineered Deletions of HIV Replicate Conditionally to Reduce Disease in Nonhuman Primates. Pitchai, F.N.N., E.J. Tanner, N. Khetan, G. Vasen, C. Levrel, A.J. Kumar, S. Pandey, T. Ordonez, P. Barnette, D. Spencer, S.Y. Jung, J. Glazier, C. Thompson, A. Harvey-Vera, H.I. Son, H.I. Son, S.A. Strathdee, L. Holguin, R. Urak, J. Burnett, W. Burgess, K. Busman-Sahay, J.D. Estes, A. Hessell, C.M. Fennessey, B.F. Keele, N.L. Haigwood, and L.S. Weinberger. Science, 2024. 385(6709): p. eadn5866. PMID[39116226].
[PubMed]. HIV_08_2024.

14. Adeno-Associated Virus (AAV)-Delivered Exosomal TAT and BiTE Molecule CD4-aCD3 Facilitate the Elimination of CD4 T Cells Harboring Latent HIV-1. Tang, X., H. Lu, P.M. Tarwater, D.L. Silverberg, C. Schorl, and B. Ramratnam. Microorganisms, 2024. 12(8). PMID[39203549]. PMCID[PMC11357122].
[PubMed]. HIV_08_2024.

15. Clonal Succession after Prolonged Antiretroviral Therapy Rejuvenates CD8(+) T Cell Responses against HIV-1. White, E., L. Papagno, A. Samri, K. Sugata, B. Hejblum, A.R. Henry, D.C. Rogan, S. Darko, P. Recordon-Pinson, Y. Dudoit, S. Llewellyn-Lacey, L.A. Chakrabarti, F. Buseyne, S.A. Migueles, D.A. Price, M.A. Andreola, Y. Satou, R. Thiebaut, C. Katlama, B. Autran, D.C. Douek, and V. Appay. Nature Immunology, 2024. 25(9): p. 1555-1564. PMID[39179934].
[PubMed]. HIV_08_2024.

16. Effective in vivo Reactivation of HIV-1 Latency Reservoir Via Oral Administration of EK-16A-SNEDDS. Yang, J., C. Shi, Y. Cheng, Y. Zhu, X. Yang, Y. Liang, H. Liang, Q. Lin, M. Li, J. Xun, J. Liu, C. Yin, J. Qi, and H. Zhu. European Journal of Pharmaceutics and Biopharmaceutics, 2024. 201: p. 114353. PMID[38885911].
[PubMed]. HIV_08_2024.

17. 2'-Β-Methylselenyl Nucleos(t)ide Analogs as Reverse Transcriptase Inhibitors against Diverse HIV Mutants. Yoshida, Y., Y. Niimi, D. Fushihara, H. Katakura, R. Fukui, H. Murase, F. Tomoike, F. Hashiya, T. Murakami, E.N. Kodama, T. Suzuki, K. Yasukawa, Y. Kimura, and H. Abe. Bioorganic & Medicinal Chemistry, 2024. 110: p. 117813. PMID[38954919].
[PubMed]. HIV_08_2024.

18. Extracellular Domain, Hinge, and Transmembrane Determinants Affecting Surface CD4 Expression of a Novel Anti-HIV Chimeric Antigen Receptor (CAR) Construct. Zenere, G., C. Wu, C.C. Midkiff, N.M. Johnson, C.P. Grice, W.C. Wimley, A. Kaur, and S.E. Braun. Plos One, 2024. 19(8): p. e0293990. PMID[39133676]. PMCID[PMC11318886].
[PubMed]. HIV_08_2024.

19. ORC1 Enhances Repressive Epigenetic Modifications on HIV-1 LTR to Promote HIV-1 Latency. Zhou, M., T. Yang, M. Yuan, X. Li, J. Deng, S. Wu, Z. Zhong, Y. Lin, W. Zhang, B. Xia, Y. Wu, L. Wang, T. Chen, R. Liu, T. Pan, X. Ma, L. Li, B. Liu, and H. Zhang. Journal of Virology, 2024. 98(8): p. e0003524. PMID[39082875]. PMCID[PMC11334468].
[PubMed]. HIV_08_2024.

20. Highly Potent and Broadly Neutralizing Anti-CD4 Trimeric Nanobodies Inhibit HIV-1 Infection by Inducing CD4 Conformational Alteration. Zhu, L., B. Huang, X. Wang, F. Ni, M. Ao, R. Wang, B. Zheng, C. Chen, J. Xue, L. Zhu, C. Yang, L. Shi, S. Geng, J. Hu, M. Yang, D. Zhang, P. Yang, M. Li, Y. Li, Q. Hu, S. Ye, P. Zheng, H. Wei, Z. Wu, L. Zhang, Y. Wang, Y. Liu, and X. Wu. Nature Communications, 2024. 15(1): p. 6961. PMID[39138183]. PMCID[PMC11322561].
[PubMed]. HIV_08_2024.

Patent Citations

21. Synthesis of Nucleotide analog antiviral prodrugs in intermediate and long-acting formulations treating RNA viral infections in mammals. Hostetler, K.Y., J. Beadle, N. Valiaeva, and R.T. Schooley. Patent. 2024. WO2024-US131462024159117: 175pp.
[Patent]. HIV_08_2024.